肿瘤防治研究2025，Vol.52Issue(6)：527-532,6.DOI:10.3971/j.issn.1000-8578.2025.24.1280
免疫检查点抑制剂联合抗血管生成药物治疗晚期非小细胞肺癌的研究进展
Research Progress of Immune Checkpoint Inhibitors Combined with Anti-Angiogenic Drugs in Treatment of Advanced Non-Small Cell Lung Cancer
曾爱菊 1马代远1
作者信息
- 1. 637000 南充,川北医学院附属医院肿瘤科||637000 南充,川北医学院临床医学院
- 折叠
摘要
Abstract
The use of immune checkpoint inhibitors(ICIs)improves the prognosis of patients with advanced non-small cell lung cancer(NSCLC).However,some patients still fail to benefit from them.In recent years,studies have demonstrated that the combination of antiangiogenic agents with ICIs can enhance the antitumor effect,and guidelines at home and abroad have suggested that the combination of ICIs with antiangiogenic regimens can be used in patients with advanced NSCLC.Therefore,the mechanism of action and the latest clinical studies on the combination of ICIs and anti-angiogenic drugs in the treatment of advanced NSCLC were reviewed in this article to provide reference for treating advanced NSCLC.关键词
非小细胞肺癌/免疫检查点抑制剂/抗血管生成药物Key words
Non-small cell lung cancer/Immune checkpoint inhibitors/Anti-angiogenic drugs分类
医药卫生引用本文复制引用
曾爱菊,马代远..免疫检查点抑制剂联合抗血管生成药物治疗晚期非小细胞肺癌的研究进展[J].肿瘤防治研究,2025,52(6):527-532,6.
